BOSTON and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for ...

LONDON, UK - Media OutReach Newswire - 5 June 2025 - Takeda, a global value-based, R&D-driven biopharmaceutical company, has been proudly recognized as one of the Top 10 ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today ...

XP 8121 is a combination drug meant to better control hypothyroidism, in part by moving its common therapy, levothyroxine, ...

Shares of Liminatus Pharma rose in post-market trading after the pre-clinical stage biopharmaceutical company said it regained compliance with Nasdaq listing requirements. The stock rallied 77% to $22 ...

The biopharmaceutical sector is underpinned by a unique ecosystem that combines public funding for basic research, university ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” first quarter 2025 investor letter.

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales ...

Canadian biotechnology company Quantum Biopharma has bought an additional $1 million worth of Bitcoin and other cryptocurrencies, taking its total holdings to around $4.5 million.

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...